Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024. In the quarter to June 2026, revenue grew 14.9%, EPS fell 24.8%, free cash flow grew 10.8% and total debt fell 9.90%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.

320.86 0.34 −0.11%
Market cap
$12.7B
P/E
78.4×
Fwd P/E
63.5×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

8 8 7 6
ROE
13.32% 13.78% 12.73% 11.37%
ROA
10.18% 10.58% 9.80% 8.80%
ROIC
11.87% 13.09% 13.32% 13.13%
Return on Tangible Assets
15.33% 15.44% 14.28% 12.77%
Average Days of Receivables
50.20 49.41 46.00 46.18
Free Cash Flow per Share
3.91 4.49 5.42 5.49
Free Cash Flow
152.62 174.93 212.73 215.91
Other line items

Show all line items

Columns are period end dates